Cargando…
External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease
Van Trommel et al have previously shown that serum human chorionic gonadotropin (hCG) cutoff levels can provide early prediction of resistance to first-line methotrexate (MTX) in patients with persistent trophoblastic disease (PTD). In this study, we validate this approach of prediction of resistanc...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661779/ https://www.ncbi.nlm.nih.gov/pubmed/19293810 http://dx.doi.org/10.1038/sj.bjc.6604849 |
_version_ | 1782165819770273792 |
---|---|
author | Kerkmeijer, L G Thomas, C M Harvey, R Sweep, F C Mitchell, H Massuger, L F Seckl, M J |
author_facet | Kerkmeijer, L G Thomas, C M Harvey, R Sweep, F C Mitchell, H Massuger, L F Seckl, M J |
author_sort | Kerkmeijer, L G |
collection | PubMed |
description | Van Trommel et al have previously shown that serum human chorionic gonadotropin (hCG) cutoff levels can provide early prediction of resistance to first-line methotrexate (MTX) in patients with persistent trophoblastic disease (PTD). In this study, we validate this approach of prediction of resistance to single-agent chemotherapy in an independent and larger cohort of PTD patients using a different hCG assay. Receiver operating characteristics (ROC) curves were constructed to determine hCG cutoff levels and sensitivity between patients cured on single-agent chemotherapy (control group) and patients requiring change to combination chemotherapy (study group). Receiver operating characteristics analysis identified an hCG cutoff value of 737 IU l(−1) that enabled us to predict the subsequent development of single-agent chemotherapy resistance in 52% of patients before their fourth MTX course at 97.5% specificity. This would have enabled an earlier switch to combination chemotherapy reducing the MTX exposure by an average of 2.5 courses. The present findings confirm that serum hCG cutoff levels predict resistance to single-agent therapy earlier than traditional methods. Change to combination chemotherapy should be considered for patients whose serum hCG levels exceed these hCG cutoff values. For patients not exceeding the hCG cutoff levels, static or rising hCG levels should still be included in the criteria for change of chemotherapy. |
format | Text |
id | pubmed-2661779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-26617792010-03-24 External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease Kerkmeijer, L G Thomas, C M Harvey, R Sweep, F C Mitchell, H Massuger, L F Seckl, M J Br J Cancer Molecular Diagnostics Van Trommel et al have previously shown that serum human chorionic gonadotropin (hCG) cutoff levels can provide early prediction of resistance to first-line methotrexate (MTX) in patients with persistent trophoblastic disease (PTD). In this study, we validate this approach of prediction of resistance to single-agent chemotherapy in an independent and larger cohort of PTD patients using a different hCG assay. Receiver operating characteristics (ROC) curves were constructed to determine hCG cutoff levels and sensitivity between patients cured on single-agent chemotherapy (control group) and patients requiring change to combination chemotherapy (study group). Receiver operating characteristics analysis identified an hCG cutoff value of 737 IU l(−1) that enabled us to predict the subsequent development of single-agent chemotherapy resistance in 52% of patients before their fourth MTX course at 97.5% specificity. This would have enabled an earlier switch to combination chemotherapy reducing the MTX exposure by an average of 2.5 courses. The present findings confirm that serum hCG cutoff levels predict resistance to single-agent therapy earlier than traditional methods. Change to combination chemotherapy should be considered for patients whose serum hCG levels exceed these hCG cutoff values. For patients not exceeding the hCG cutoff levels, static or rising hCG levels should still be included in the criteria for change of chemotherapy. Nature Publishing Group 2009-03-24 2009-03-17 /pmc/articles/PMC2661779/ /pubmed/19293810 http://dx.doi.org/10.1038/sj.bjc.6604849 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Kerkmeijer, L G Thomas, C M Harvey, R Sweep, F C Mitchell, H Massuger, L F Seckl, M J External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title | External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title_full | External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title_fullStr | External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title_full_unstemmed | External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title_short | External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
title_sort | external validation of serum hcg cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661779/ https://www.ncbi.nlm.nih.gov/pubmed/19293810 http://dx.doi.org/10.1038/sj.bjc.6604849 |
work_keys_str_mv | AT kerkmeijerlg externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT thomascm externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT harveyr externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT sweepfc externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT mitchellh externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT massugerlf externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease AT secklmj externalvalidationofserumhcgcutofflevelsforpredictionofresistancetosingleagentchemotherapyinpatientswithpersistenttrophoblasticdisease |